Immuron (IMRN) Shares Outstanding (2016 - 2025)
Immuron (IMRN) posted quarterly Shares Outstanding (Entity) of $230.9 million for Q2 2025, up 1.35% year-over-year from $227.9 million in Q2 2024, and up 1.35% quarter-over-quarter from $227.9 million in Q2 2024.
Immuron (IMRN) Shares Outstanding (2016 - 2025) Analysis & Trends
Immuron's Shares Outstanding (Entity) history runs 9 years deep, the most recent figure standing at $230.9 million for Q2 2025.
- In Q2 2025, Shares Outstanding (Entity) rose 1.35% year-over-year to $230.9 million; the TTM figure through Jun 2025 stood at $230.9 million (up 1.35% YoY), while the FY2025 annual figure was $230.9 million, up 1.35% from the prior year.
- Shares Outstanding (Entity) for Q2 2025 stood at $230.9 million, up from $227.9 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $230.9 million in Q2 2025, with the low at $221.1 million in Q2 2021.
- The 5-year median for Shares Outstanding (Entity) is $227.8 million (2022), against an average of $227.3 million.
- The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Entity) gained 2.95% in 2022, then changed 0.0% in 2023.
- Immuron's Shares Outstanding (Entity) stood at $221.1 million in 2021, then advanced by 3.05% to $227.8 million in 2022, then changed by 0.0% to $227.8 million in 2023, then advanced by 0.03% to $227.9 million in 2024, then rose by 1.35% to $230.9 million in 2025.
- Business Quant data shows IMRN's Shares Outstanding (Entity) at $230.9 million in Q2 2025, $227.9 million in Q2 2024, and $227.8 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Immuron | 6.75 Mn | 6.73 Mn | - | 5.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 2, 2025 | 230.94 Mn |
| Jun 30, 2025 | 230.94 Mn |
| Dec 31, 2024 | 227.86 Mn |
| Sep 9, 2024 | 227.86 Mn |
| Jun 30, 2024 | 227.86 Mn |
| Dec 31, 2023 | 227.80 Mn |
| Sep 28, 2023 | 227.80 Mn |
| Aug 30, 2023 | 227.80 Mn |
| Jun 30, 2023 | 227.80 Mn |
| Dec 31, 2022 | 227.80 Mn |
| Aug 31, 2022 | 227.58 Mn |
| Jun 30, 2022 | 227.58 Mn |
| Dec 31, 2021 | 221.06 Mn |
| Jun 30, 2021 | 221.06 Mn |
| Dec 31, 2020 | 176.39 Mn |
| Sep 1, 2020 | 176.39 Mn |
| Jun 30, 2020 | 176.39 Mn |
| Dec 31, 2019 | 175.50 Mn |
| Jun 30, 2019 | 144.74 Mn |
| Dec 31, 2018 | 136.37 Mn |